

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

Rakovina Therapeutics Inc. (the “Company”)
2201 – 8 Smithe Mews
Vancouver, British Columbia
Canada, V6B 0A5

Item 2: Date of Material Change

November 17, 2021.

Item 3: News Release

A news release announcing the material change was issued and disseminated by [CNW Group] on November 23, 2021 and filed on the System for Electronic Document Analysis and Retrieval (“SEDAR”) (www.sedar.com).

Item 4: Summary of Material Change

On November 23, 2021, the Company announced the resignation of Dr. Julie M. Cherrington from the board of directors of the Company. Dr. Cherrington will continue to serve the Company as a member of the Scientific Advisory Board.

Item 5: Full Description of Material Change

On November 23, 2021, the Company announced the resignation of Dr. Julie M. Cherrington from the board of directors of the Company. Dr. Cherrington will continue to serve the Company as a member of the Scientific Advisory Board.

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

Not applicable.

Item 8: Executive Officer

For further information, please contact David Hyman, Chief Financial Officer of the Company at +1 (403) 613-1453.

Item 9: Date of Report

November 24, 2021.